Alimera Sciences - ALIM Profit before interest, taxes and amortization

Alimera Sciences (ALIM) is currently scaling the commercial success of the Iluvien implant. The GURU.Markets portal features a chart of absolute EBITDA dynamics, where represents the current value of the metric. Business growth is supported by patents for sustained-release drug delivery in the retina. Sales efficiency is driven by close collaboration with ophthalmologists and distributors to implement innovative treatment methods.

alimerasciences.com (ALIM) Profit before payment of interest, taxes and amortization: for the period 07/04/2022 - 11/11/2026

Summary analytical data breakdowns for Alimera Sciences, Inc. (ALIM)

- market value and analyst target forecast:

Market Price Alimera Sciences Inc|ALIM - Consensus Target

- issuer market value details:

Market Value Alimera Sciences|ALIM - Enterprise Value

- book capitalization data:

Net Asset Value per Share Alimera Sciences|ALIM - Company Book Value|Market Capitalization to Book Value alimerasciences.com|ALIM - Company Total Assets

- business debt structure and liquidity details:

- earnings and market multiples details:

ALIM - Company Net Income|Expected Net Income Alimera Sciences|ALIM - P/E Multiple|Forward P/E Multiple Alimera Sciences Inc|ALIM - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Alimera Sciences|ALIM - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Alimera Sciences|ALIM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months alimerasciences.com|ALIM - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Alimera Sciences

Summary company analytics:ALIM Alimera Sciences

Original product of Alimera Sciences Inc

To assess the credit quality of Alimera Sciences (ALIM), the analyst examines daily operating profit, which currently stands at . Analyzing changes in EBITDA_Co allows for the identification of hidden accounting anomalies and cost volatility, which, combined with stable utilization of certified implant production lines, confirms cash flow resilience and protects the investor from overpaying for the asset.

Competitors of Alimera Sciences (ALIM)

Alcon Corp (ALC) - Profit before interest, taxes and amortization|BLCO: Operating profit before deduction of amortization|Profit before interest, taxes and amortization glaukos.com|APLS: Operating profit EBITDA|Profit before interest, taxes and amortization Belite Bio Pharma (BLTE)|Profit before payment of interest, taxes and amortization Ocular Therapeutix Corp|Harrow Corp (HROW) - Operating income before deduction of amortization|Operating profit EBITDA VRDN|Operating profit EBITDA lenz-tx.com (LENZ)|Profit before payment of interest, taxes and amortization Oculis Holding OCS|EyePoint Pharmaceuticals Inc - Profit before payment of interest, taxes and amortization|Kodiak Pharma - Operating profit EBITDA|Operating income before deduction of amortization Aldeyra Therapeutics ALDX|kalarx.com (KALA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Opus Genetics|OKYO (OKYO Pharma Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Adverum ADVM|Profit before payment of interest, taxes and amortization Outlook Pharma (OTLK)|CLSD (Clearside Corp) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA NBY (NovaBay Pharmaceuticals, Inc.)|Operating profit EBITDA Kiora Pharmaceuticals Inc. KPRX|EYEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization GHSI (Guardion Health Sciences, Inc.)|Ocuphire (OCUP) - Profit before payment of interest, taxes and amortization|OPT - Operating income before deduction of amortization